[Huixun Express] The 2019 China Biomedical Innovation Cooperation Conference has come to a successful conclusion. Looking forward to seeing you next year!
Drugfocus Drug Research Vision Today
"2019 China Biopharma Innovation Cooperation Conference " was held in Shanghai from September 26 to 27. The conference was hosted by Marbley Medical , Shanghai Biopharma Industry Association, . Shanghai Pudong New District Bioindustry Industry Association, the Commerce Office of the US Embassy and Consulates in China, Zhangjiang Life and Health Industry (Incubation) Alliance, Shanghai Junrun Network Technology Co., Ltd. , supported by Baihua Association, Hong Kong Biotechnology Association, Tongyiyi, New Drug Founders Club, Shanghai Equity Investment Association, Yaodu, Xialan Investment, Haimen Science and Technology Park, Tuhu.com, Guangdong Medical Valley, Wuhan Donghu National Independent Innovation Demonstration Zone Biomedical Industry Association and other institutions.
Personal Conference
Personal Conference was chaired by Yehui Pharmaceutical Dr. Huaye , and Teacher Dong Shupei from Shanghai Science and Technology Commission was invited to give a detailed interpretation of Shanghai's biomedical industry planning and policies.
Shanghai Junshi Biologics Dr. Feng Hui shared the topic of "Opportunities, Challenges and Response to China's Innovative Drugs". WuXi AppTec Ji Qunsheng Ph.D. gave a wonderful report on "Immune Translational Medicine Platform to Aid the Research and Development of New Drugs on Tumor Immunity".
Then, Mr. Yu Cong, Chairman of Shanghai Changxing Marine Equipment Park, took the stage to discuss Changxing, and won the future. The title is Shanghai Changxing Marine Equipment Industrial Park to promote investment, and introduced the park's future plans and policies in detail.
Interactive roundtable discussion "Deepening the drug review and approval system and speeding up the research and development and marketing of new drugs in China" was hosted by Dr. Hua Ye of Yehui Pharmaceuticals , and together with Dr. Zhang Haizhou of Boji Biologics, Dr. Yang Jianxin of jingshi Pharmaceuticals and Dr. Lu Yuzhen of Roche (China), had an in-depth discussion for an hour.
point forum 1 Innovative biomedical technology prospect
point forum 1 Heyuan Biologics Dr. Lu Lulu served as the conference host. In an interactive roundtable discussion on the topic of "Exploring the development and innovative cooperation model of tumor immunotherapy antibodies", Yiming Angke Tian Wenzhi was the host guest, and Dr. Yang Jianxin of Jieshi Pharmaceuticals, Dr. Elixiron Immunotherapeutics Dr. Chen Hongkai, and Dr. Liao Maijing of Hebo Pharmaceuticals were the discussion guests.
Dr. Zhang Yi of Hualing Pharmaceuticals focuses on introducing the mechanism of action and clinical research progress of the new generation of diabetes drug for - the glucose kinase activator Dorzagliatin regulating blood glucose homeostasis . Mr. Norbert Prenzel from SOTIO, shared the topic of Building an Oncology Specialty Pharma Company .
Mr. Yang Xiaodong of KPMG shared the information management of drug research and development expense traceability . Dr. Luo Jin of Jiangsu Antai Biologics gave a keynote speech on the topic of "Dendritic Cell Therapy Technology based on SEA-MAP Load". The interactive roundtable discussion hosted by Heyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-Hiyuan Bio-
was hosted by Mr. Ye Yin, Ping An Securities, and participated by Mr. Gao Lei, Mr. Jun Shengtai, Ms. Wu Yixia, Mr. Zhou Yujian of Mifang Capital, and Dr. Siludi Xu Meng of , focusing on investment and financing opportunities in China's pharmaceutical industry.
Sub-forum 2 Biomedical R&D and Cooperation
Clover Biologics Dr. Dong Min, serves as the host of the second conference of the sub-forum and the host of the first roundtable discussion in the afternoon. Under the topic of the research and development difficulties and market prospects of macromolecular biological innovative drugs, Dr. Wei Ziping of Bailiscon, Dr. Shanbo of Deqi Pharmaceuticals, and Dr. Chen Zhaorong of .
Regarding the current research status and risk control of tumor immunotherapy drugs, National Shanghai New Drug Safety Evaluation Research Center Ma Jing Dr. expressed his views. Shenzhen Smart Pharmaceutical Technology Huang Tao, general manager of , shared with everyone the application of machine learning technology in the research and development of new drugs . BaioSai Tu Shen Yuelei introduces a new model of antibody drug development: a one-stop R&D platform based on the effects of whole-human antibody RenMab mice and in vivo drug effects. Sanyou Biological Jinbo total gave a keynote speech on , an innovative antibody drug integrated high-throughput R&D service platform.
Dr. Peng Bin of the Anmai Bio shared the research and development of bispecific antibodies and future layout of . Dr. Luo Wen of Soyuan Bio delivered a keynote speech on starting from China, the world-oriented precision medicine: Suyuan Bio's unique innovative drug model . Dr. Wu Youling of Teres Pharmaceutical also shared his views on the past, present and future of ADC product development.
Pfizer Ph.D. introduces how to research and development of new drugs based on innovation and cooperation. Tuozhen Bio-Dr. Zhou Zhou brought to . The current status and strategies of NASH new drugs for non-alcoholic steatohepatitis NASH. Gaocheng Biomedicine Dr. He Qi shared the application and outlook of the high-throughput single-cell analysis platform in innovative drug research and development . In response to the oncolytic virus that is currently hotly discussed, the conference invited two experts in this field - Yinuo Wei Pharmaceutical Dr. Guoying and Dr. Liu Binlei of Binhui Biologics to give wonderful reports respectively.
Mr. Nie Yan and Mr. Gao Huanyong from Shengzhi Law Firm in the United States gave keynote speeches on the international perspective of patent applications in the field of biopharmaceuticals. and Dr. Li Fang of Platinum Pharmaceuticals shared the " full human antibody transgenic mouse platform helps develop innovative tumor immune therapy ". Ms. Christy Ma of Lion TCR brought a keynote speech by Opportunity and Barrier in Cell Therapy Clinical Research.
US CST Mr. Liu Ming gave a keynote speech on the multidisciplinary cooperation of PTMscan® technology to promote the discovery and commercialization of oncology biomarker . Beijing PanGenogene Wang Di Zong shared the topic of "HTM6 based on biomarker detection based on NGS platform to accurately assist drug research and development ". Mr. Yang Xin, investment promotion director of Shanghai Lingang Changxing Science and Technology City, , as a representative of Lingang Changxing Science and Technology City, shared the theme report of " Lingang Changxing - Create Value for the Industry ".
Roundtable discussion with Dr. Li Jing of Yaodu hosted by the guests - "New methods and new technologies of drug research and development in are emerging in the city, and Parexel Dr. Feng Sheng, Dr. Guo Xiang of BeiGene, Dr. Xue Fubo of Junshi Biotechnology and Dr. Medidate Chen Zhiyang were invited.
Taiwan American Biomedical Special Session
This conference was divided into two major biomedical special sessions in Taiwan and the United States. As the host of the Taiwan special session, Dr. Zhang Haoteng of Rongyu Capital, , invited Dr. Chen Hongkai of Elixiron Immunotherapeutics Inc, , Dr. Shen Weihong of Taiwan Pharmaceuticals, Dr. Jing Kai Bio-Quan Zhu, Dr. Tairui Bio-Quanxian, and Dr. Wang Chaohui, the original doctor.
Deputy Director Huang Chengchao, People's Government of Anting Town, Jiading District, Shanghai, , seized the development opportunities and created a highland for precision medical industry , and made an industrial recommendation for Anting Town. Taizhou Pharmaceutical High-tech Park Management Committee Mr. Shike introduced the functions and roles of professional parks in the innovation and development of biomedical medicine.
The US special session invited Frost Sullivan to consult Mr. Mao Hua, , American Feihan Law Firm lawyers, , Sorrento Therapeutics Inc. Dr. Hui LI, Merck Wu Min, Dr. Wang Yajun of Illumina, Berkeley Lights, Ms. Yang Yuehong of Inc, and Ms. Angela Feng of Xynomic Pharmaceuticals, to deliver wonderful reports.
special thanks
This conference was held on the evening of the 26th with the support of Shanghai Changxing Marine Equipment Park , Lingang Changxing Science and Technology Park and Shanghai Aopu Enterprise Service Center . Nearly 150 well-known people, including relevant government officials, industry and association leaders, well-known enterprises, etc., gathered together to build a feast for the global biopharmaceutical industry. Thank you again for your strong support from every guest present!
With the help of all industry experts and enterprises, the conference concluded perfectly! Thanks to the strong support of 70+ speakers, 10+ cooperative institutions, 30+ cooperative enterprises, and 40+ cooperative media ! The organizing committee will continue to work closely with outstanding industry experts and enterprises to build the most influential platform for China's biomedicine. Looking forward to meeting you with 2020 Second China Biomedical Innovation Cooperation Conference !
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-